Human L‑asparaginase: Acquiring knowledge of its activation (Review)
- Authors:
- Stephanie Bath De Morais
- Tatiana De Arruda Campos Brasil De Souza
-
Affiliations: Structural and Computational Proteomics Laboratory, Carlos Chagas Institute, FIOCRUZ‑PR, Curitiba, Parana 80320‑290, Brazil - Published online on: February 24, 2021 https://doi.org/10.3892/ijo.2021.5191
- Article Number: 11
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Lang S: Über desamidierung im Tierkörper. Beitr hem Physiol Pathol. 5:321–345. 1904. | |
|
Fürth O and Friedmann M: Über die Verbreitung asparaginspaltender Organfermente. Biochem Z. 26:435–440. 1910. | |
|
Clementi A: La Désamidation Enzymatique De L'asparagine Chez Les Différentes Espéces Animales Et La Signification Physio Logique De Sa Presence Dans L'organisme. Arch Int de Physiol. 19:369–398. 1922. | |
|
Kidd JG: Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med. 98:565–582. 1953. View Article : Google Scholar : PubMed/NCBI | |
|
Broome JD: Evidence that the L-Asparaginase activity of guinea pig serum is responsible for its Antilymphoma Effects. Nature. 191:1114–1115. 1961. View Article : Google Scholar | |
|
Broome JD: Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med. 118:99–120. 1963. View Article : Google Scholar : PubMed/NCBI | |
|
Mashburn LT and Wriston JC: Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys. 105:450–452. 1964. View Article : Google Scholar : PubMed/NCBI | |
|
Broome JD: Antilymphoma activity of L-asparaginase in vivo: Clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth. J Natl Cancer Inst. 35:967–974. 1965.PubMed/NCBI | |
|
Dolowy WC, Henson D, Cornet J and Sellin H: Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 19:1813–1819. 1966. View Article : Google Scholar : PubMed/NCBI | |
|
Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallai L, Tan CC, Clarkson BD, Golbey RB, Krakoff IH, Karnofsky DA, et al: Toxicity of E. coli L-asparaginase in man. Cancer. 25:253–278. 1970. View Article : Google Scholar : PubMed/NCBI | |
|
Hill JM, Roberts J, Loeb E, Khan A, MacLellan A and Hill RW: L-asparaginase therapy for leukemia and other malignant neoplasms. JAMA. 202:882–888. 1967. View Article : Google Scholar : PubMed/NCBI | |
|
Salzer WL, Asselin BL, Plourde PV, Corn T and Hunger SP: Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia. Ann N Y Acad Sci. 1329:81–92. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
American Cancer Society: Cancer Facts and Figures 2019. American Cancer Society; Atlanta, GA: 2019 | |
|
Terwilliger T and Abdul-Hay M: Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer J. 7:e5772017. View Article : Google Scholar : PubMed/NCBI | |
|
American Cancer Society: Leukemia-Acute Lymphocytic (Adults). American Cancer Society; Atlanta, GA: 2014 | |
|
Cooper SL and Brown PA: Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 62:61–73. 2015. View Article : Google Scholar : | |
|
Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, et al: Results of the Dana-Farber cancer institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 109:896–905. 2007. View Article : Google Scholar | |
|
Pui CH and Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med. 354:166–178. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pui CH and Evans WE: Acute lymphoblastic leukemia. N Engl J Med. 339:605–615. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM and Gaynon PS: Augmented Post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 338:1663–1671. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Gaynon P, Trigg M, Heerema N, Sensel M, Sather H, Hammond G and Bleyer W: Children's cancer group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 14:2223–2233. 2000. View Article : Google Scholar | |
|
Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 95:3310–3322. 2000.PubMed/NCBI | |
|
Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD and Peterson BA: Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: Results of cancer and leukemia group B study 9251. J Clin Oncol. 19:4014–4022. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Patte C: The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 97:3370–3379. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber consortium protocol 91-01. Blood. 97:1211–1218. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Pui CH: Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 104:2690–2696. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rytting ME: Role of L-asparaginase in acute lymphoblastic leukemia: Focus on adult patients. Blood Lymphatic Cancer Targets Ther. 2:117–124. 2012. View Article : Google Scholar | |
|
American Cancer Society: Chemotherapy for Childhood Leukemia. American Cancer Society; Atlanta, GA: 2019 | |
|
Pui CH, Campana D and Evans WE: Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol. 2:597–607. 2001. View Article : Google Scholar | |
|
Gleissner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, et al: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 99:1536–1543. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pui CH, Relling MV and Downing JR: Acute lymphoblastic leukemia. N Engl J Med. 350:1535–1548. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Armstrong SA and Look AT: Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 23:6306–6315. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mancini M: A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): Analysis of the GIMEMA 0496 protocol. Blood. 105:3434–3441. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
National Cancer Institute (NIH): Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)-Health Professional Version, NIH 2020. | |
|
Li BS, Gu LJ, Luo CY, Li WS, Jiang LM, Shen SH, Jiang H, Shen SH, Zhang B, Chen J, et al: The downregulation of asparagine synthetase expression can increase the sensitivity of cells resistant to l-asparaginase. Leukemia. 20:2199–2201. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Song P, Ye L, Fan J, Li Y, Zeng X, Wang Z, Wang S, Zhang G, Yang P, Cao Z and Ju D: Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells. Oncotarget. 6:3861–3873. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M and Pui CH: L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer. 117:238–249. 2011. View Article : Google Scholar | |
|
Avramis VI: Asparaginases: Biochemical pharmacology and modes of drug resistance. Anticancer Res. 32:2423–2437. 2012.PubMed/NCBI | |
|
Ueno T, Ohtawa K, Mitsui K, Kodera Y, Hiroto M, Matsushima A, Inada Y and Nishimura H: Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia. 11:1858–1861. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Yu M, Henning R, Walker A, Kim G, Perroy A, Alessandro R, Virador V and Kohn EC: L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med. 16:2369–2378. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, et al: Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 122:3521–3532. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Fan J, Zhang X, Shen W, Cao Z, Yang P, Xu Z and Ju D: Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy. Appl Microbiol Biotechnol. 100:9145–9161. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lorenzi PL, Claerhout S, Mills GB and Weinstein JN: A curated census of autophagy-modulating proteins and small molecules. Autophagy. 10:1316–1326. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Purwaha P, Lorenzi PL, Silva LP, Hawke DH and Weinstein JN: Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells. Metabolomics. 10:909–919. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Panosyan EH, Wang Y, Xia P, Lee WN, Pak Y, Laks DR, Lin HJ, Moore TB, Cloughesy TF, Kornblum HI and Lasky JL III: Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Mol Cancer Res. 12:694–702. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, et al: Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 180:895–903. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M, Warkentin P, Gilchrist GS, Cohen MD, Shina D and Meadows AT: Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol. 19:2390–2396. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bansal S, Srivastava A, Mukherjee G, Pandey R, Verma AK, Mishra P and Kundu B: Hyperthermophilic asparaginase mutants with enhanced substrate affinity and antineoplastic activity: Structural insights on their mechanism of action. FASEB J. 26:1161–1171. 2012. View Article : Google Scholar | |
|
Roth G, Nunes JES, Rosado LA, Bizarro CV, Volpato C, Nunes CP, Renard G, Basso LA, Santo DS and Chies JM: Recombinant Erwinia caratovora L-asparaginase II production in Escherichia coli Fed-batch cultures. Br J Chem Engineering. 30:245–256. 2013. View Article : Google Scholar | |
|
Tong WH, van der Sluis IM, Alleman CJM, van Litsenburg RRL, Kaspers GJL, Pieters R and Uyl-de Groot CA: Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: The impact of expensive chemotherapy. Haematologica. 98:753–759. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Müller HJ, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schütz V, Henze G, Casimiro da Palma J, Ritter J, et al: Pegylated asparaginase (Oncaspar) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 110:379–384. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Willer A, Gerss J, König T, Franke D, Kühnel HJ, Henze G, von Stackelberg A, Möricke A, Schrappe M, Boos J and Lanvers-Kaminsky C: Anti-Escherichia coli asparaginase anti-body levels determine the activity of second-line treatment with pegylated E coli asparaginase: A retrospective analysis within the ALL-BFM trials. Blood. 118:5774–5782. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Højfeldt SG, Wolthers BO, Tulstrup M, Abrahamsson J, Gupta R, Harila-Saari A, Heyman M, Henriksen LT, Jónsson ÒG, Lähteenmäki PM, et al: Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008. Br J Haematol. 184:405–417. 2019. View Article : Google Scholar | |
|
Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, et al: Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 126:69–75. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SH, Pei D, Yang W, Cheng C, Jeha S, Cox NJ, Evans WE, Pui CH and Relling MV: Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 88:191–196. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hijiya N and van der Sluis IM: Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 57:748–757. 2016. View Article : Google Scholar : | |
|
van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, Escherich G, Goulden N, Mondelaers V, Sanchez de Toledo J, Rizzari C, Silverman LB and Whitlock JA: Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 101:279–285. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tong WH, Pieters R, Tissing WJE and van der Sluis IM: Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase. Haematologica. 99:e102–e104. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Müller HJ and Boos J: Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 28:97–113. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JK, Kang S, Wang X, Rosales JL, Gao X, Byun HG, Jin Y, Fu S, Wang J and Lee KY: HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway. Blood. 133:2222–2232. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SH: Asparaginase therapy in pediatric acute lymphoblastic leukemia: A focus on the mode of drug resistance. Pediatr Neonatol. 56:287–293. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Aslanian AM and Kilberg MS: Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J. 358:59–67. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Su N, Pan YX, Zhou M, Harvey RC, Hunger SP and Kilberg MS: Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer. 50:274–279. 2008. View Article : Google Scholar | |
|
Kang SM, Rosales JL, Meier-Stephenson V, Kim S, Lee KY and Narendran A: Genome-wide loss-of-function genetic screening identifies opioid receptor µ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Oncogene. 36:5910–5913. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Patel N, Krishnan S, Offman MN, Krol M, Moss CX, Leighton C, van Delft FW, Holland M, Liu J, Alexander S, et al: A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest. 119:1964–1973. 2009.PubMed/NCBI | |
|
Avramis VI and Tiwari PN: Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 1:241–254. 2006. | |
|
Ghasemian A, Al-Marzoqi AH, Al-Abodi HR, Alghanimi YK, Kadhum SA, Shokouhi Mostafavi SK and Fattahi A: Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives. J Cell Physiol. 234:19271–19279. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sokolov NN, Eldarov MA, Pokrovskaya MV, Aleksandrova SS, Abakumova OY, Podobed OV, Melik-Nubarov NS, Kudryashova EV, Grishin DV and Archakov AI: Bacterial recombinant L-asparaginases: Properties, structure and anti-proliferative activity. Biomed Khim. 61:312–324. 2015.In Russian. View Article : Google Scholar : PubMed/NCBI | |
|
Krishnapura PR, Belur PD and Subramanya S: A critical review on properties and applications of microbial l-asparaginases. Crit Rev Microbiol. 42:720–737. 2016. | |
|
Chiu M, Taurino G, Bianchi MG, Kilberg MS and Bussolati O: Asparagine synthetase in cancer: Beyond acute lymphoblastic leukemia. Front Oncol. 9:14802019. View Article : Google Scholar | |
|
Egler RA, Ahuja SP and Matloub Y: L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 7:62–71. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee MB and Bridges JM: L-Asparaginase activity in human and animal sera. Nature. 217:758–759. 1968. View Article : Google Scholar : PubMed/NCBI | |
|
Oinonen C, Tikkanen R, Rouvinen J and Peltonen L: Three-dimensional structure of human lysosomal aspartylglucosaminidase. Nat Struct Biol. 2:1102–1108. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Sugimoto H, Odani S and Yamashita S: Cloning and expression of cDNA encoding rat liver 60-kDa lysophospholipase containing an asparaginase-like region and ankyrin repeat. J Biol Chem. 273:12536–12542. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Bush LA, Herr JC, Wolkowicz M, Sherman NE, Shore A and Flickinger CJ: A novel asparaginase-like protein is a sperm auto-antigen in rats. Mol Reprod Dev. 247:233–247. 2002. View Article : Google Scholar | |
|
Evtimova V, Zeillinger R, Kaul S and Weidle UH: Identification of CRASH, a gene deregulated in gynecological tumors. Int J Oncol. 24:33–41. 2004. | |
|
Nomme J, Su Y, Konrad M and Lavie A: Structures of Apo and product-bound human L-asparaginase: Insights into the mechanism of autoproteolysis and substrate hydrolysis. Biochemistry. 51:6816–6826. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Böhme L, Bär JW, Hoffmann T, Manhart S, Ludwig HH, Rosche F and Demuth HU: Isoaspartate residues dramatically influence substrate recognition and turnover by proteases. Biol Chem. 389:1043–1053. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Michalska K and Jaskólski M: Structural aspects of l-asparaginases, their friends and relations. Acta Biochimica Pol. 53:627–640. 2006. View Article : Google Scholar | |
|
Dieterich DC, Landwehr M, Reissner C, Smalla KH, Richter K, Wolf G, Böckers TM, Gundelfinger ED and Kreutz MR: Gliap-A novel untypical L-asparaginase localized to rat brain astrocytes. J Neurochem. 85:1117–1125. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cantor JR, Stone EM, Chantranupong L and Georgiou G: The human asparaginase-like protein 1 hASRGL1 is an Ntn Hydrolase with β-aspartyl peptidase activity. Biochemistry. 48:11025–11031. 2009. View Article : Google Scholar | |
|
Brannigan JA, Dodson G, Duggleby HJ, Moody PCE, Smith JL, Tomchick DR and Murzin AG: A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature. 378:416–419. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Duggleby HJ, Tolley SP, Hill CP, Dodson EJ, Dodson G and Moody PCE: Penicillin acylase has a single-amino-acid catalytic Centre. Nature. 373:264–268. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Khan JA, Dunn BM and Tong L: Crystal Structure of human Taspase1, a crucial protease regulating the function of MLL. Structure. 13:1443–1452. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lowe J, Stock D, Jap B, Zwickl P, Baumeister W and Huber R: Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A Resolution. Science. 268:533–539. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Borek D, Michalska K, Brzezinski K, Kisiel A, Podkowinski J, Bonthron DT, Krowarsch D, Otlewski J and Jaskolski M: Expression, purification and catalytic activity of Lupinus luteus asparagine beta-amidohydrolase and its Escherichia coli homolog. Eur J Biochem. 271:3215–3226. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Irani S, Crutchfield A, Hodge K, Matthews W, Patel P, Zhang YJ and Stone E: Intramolecular cleavage of the hASRGL1 Homodimer occurs in two stages. Biochemistry. 55:960–969. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nomme J, Su Y and Lavie A: Elucidation of the specific function of the conserved threonine triad responsible for human l-Asparaginase autocleavage and substrate hydrolysis. J Mol Biol. 426:2471–2485. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Su Y, Karamitros CS, Nomme J, McSorley T, Konrad M and Lavie A: Free glycine accelerates the autoproteolytic activation of human asparaginase. Chem Biol. 20:533–540. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Cantor JR, Yogesha SD, Yang S and Chantranupong L: Uncoupling Intramolecular processing and substrate hydrolysis in the N-terminal nucleophile hydrolase hASRGL1 by circular permutation. ACS Chem Biol. 7:1840–1847. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Karamitros CS and Konrad M: Bacterial co-expression of the α and β protomers of human l-asparaginase-3: Achieving essential N-terminal exposure of a catalytically critical threonine located in the beta-subunit. Protein Expr Purif. 93:1–10. 2014. View Article : Google Scholar | |
|
Karamitros CS and Konrad M: Fluorescence-activated cell sorting of Human l-asparaginase mutant libraries for detecting enzyme variants with enhanced activity. ACS Chem Biol. 11:2596–2607. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kelo E, Noronkoski T and Mononen I: Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase. Leukemia. 23:1167–1171. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Leader B, Baca QJ and Golan DE: Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov. 7:21–39. 2008. View Article : Google Scholar | |
|
Silverstein SM, Greenbaum S and Stern R: Hyaluronidase in ophthalmology. J App Res. 12:1–13. 2012. | |
|
Grabowski GA: Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 122:33–39. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE and Desnick RJ; International Collaborative Fabry Disease Study Group: Safety and efficacy of recombinant Human α-Galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 345:9–16. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Görlinger K, Wallot M, Richards S and Voit T: Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: Results of a phase II clinical trial. Neuromuscul Disord. 15:24–31. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Schalk AM and Lavie A: Structural and kinetic characterization of guinea Pig. Biochemistry. 53:2318–2328. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y and Guo HC: Two-step dimerization for autoproteolysis to activate glycosylasparaginase. J Biol Chem. 278:3210–3219. 2003. View Article : Google Scholar | |
|
Marianayagam NJ, Sunde M and Matthews JM: The power of two: Protein dimerization in biology. Trends Biochem Sci. 29:618–625. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Morais SB, Pirolla RAS, Frota NF, Lourenzoni MR, Gozzo FC and Souza TACB: The role of the quaternary structure in the activation of human L-asparaginase. J Proteomics. 224:1038182020. View Article : Google Scholar : PubMed/NCBI | |
|
Morin A, Meiler J and Mizoue LS: Computational design of protein-ligand interfaces: Potential in therapeutic development. Trends Biotechnol. 29:159–66. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Marshall SA, Lazar GA, Chirino AJ and Desjarlais JR: Rational design and engineering of therapeutic proteins. Drug Discovery Today. 8:212–221. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Park S and Cochran J: Protein engineering and design. CRC Press; 2009, View Article : Google Scholar | |
|
Dinndorf PA, Gootenberg J, Cohen MH, Keegan P and Pazdur R: FDA drug approval summary: Pegaspargase (Oncaspar) for the first-line treatment of Children with acute lymphoblastic leukemia (ALL). Oncologist. 12:991–998. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schalk AM, Nguyen H-A, Rigouin C and Lavie A: Identification and structural analysis of an l-asparaginase enzyme from guinea pig with putative tumor cell killing properties. J Biol Chem. 289:33175–33186. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen HA, Su Y and Lavie A: Design and characterization of Erwinia chrysanthemi l-asparaginase variants with diminished l-Glutaminase activity. J Biol Chem. 291:17664–17676. 2016. View Article : Google Scholar : PubMed/NCBI |
